Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$14.75 USD
-0.13 (-0.87%)
Updated May 9, 2024 04:00 PM ET
After-Market: $14.75 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 181 - 189 ( 189 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
RPL554 is Winning the Clinical Beauty Contest in COPD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
We reiterate our OUTPERFORM rating and a 12-month price target of $25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Initiating with an OUTPERFORM and $25 PT; RPL554: A First-in-Class, Dual-Action Inhibitor for the Treatment of Serious Lung Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L